Individual Safety Report

3192074-3-00-01

EISAI, INC.
For use by user-facilities, distributors and manufacturers for MANDATORY reporting

Mfr report # A001-002-002990
U.F./Dist report #
FDA Use Only

A. Patient information

1. Patient identifier: [redacted] In confidence
2. Age at time of event: 71 Y or Date of birth:
3. Sex: [x] female [ ] male
4. Weight: 110 lbs or ____ kgs

B. Adverse event or product problem

1. [x] Adverse event and/or [ ] Product problem (e.g., defects/malfunctions)

2. Outcomes attributed to adverse event (check all that apply)
- [ ] death ____ (mm/dd/yyyy)
- [ ] life-threatening
- [x] hospitalization - initial or prolonged
- [ ] disability
- [ ] congenital anomaly
- [ ] required intervention to prevent permanent impairment/damage
- [ ] other: ____

3. Date of event (mm/dd/yyyy): 01/17/99
4. Date of this report (mm/dd/yyyy): 01/29/99

5. Describe event or problem

[redacted] a 71 year old Caucasian female patient received Aricept therapy for the treatment of Dementia.
Approx: Dec//98: The patient began Aricept therapy at an unreported dosage.

Jan/17/99 : The patient took an overdose of Aricept therapy and acetaminophen . The patient was found unresponsive / comatose by a family member in her home. The patient lives alone. The family member indicates that there was a half bottle (the bottle originally contained 30 tablets) of Aricept left in the bottle prior to the event. The patient was taken to the emergency room of a local hospital Emergency Services approximately 1:00 PM and became minimally responsive but confused. Approximately 3 :00 PM the patient's AST was 79 UI/L and ALT was normal. The patient had a heart rate in the 50's with normal QRS waves. Acetaminophen level was 380 mcg/ml . A cholinesterase level was also drawn and read as 7419 U/L (Ref Range - 5300-10,000 U/L). A Pseudocholinesterase level 1842 U/L (Ref Range 1900-3800 U/L).

6. Relevant tests/laboratory data, including dates cont.

Jan/17/99:
AST = 79UI (elevated)
ALT= Normal
Acetaminophen level was 380 mcg/ml approximately 3 hours after the patient was found.
Cholinesterase level 7410 U/L (ref Range 5300-10,000 U/L)
Pseudocholinesterase level 1842 U/L (Ref Range 1900-3800 U/L)

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.) cont.

Past Disease
DEMENTIA

DSS

FEB 5 1999

ADVERSE EVENT REPORTING SYSTEM

RECEIVED
FEB 04 1999
BY:

C. Suspect medication(s)

1. Name (give labeled strength & mfr/labeler, if known)
#1 ARICEPT (DONEPEZIL)
#2 TYLENOL (PARACETAMOL) cont.

2. Dose, frequency & route used
#1 NA (1 in 1 D), Per oral
#2 NA, Per oral

3. Therapy dates (if unknown, give duration)
#1 12/ /98 - 01/16/99
#2 01/17/99 - 01/17/99

4. Diagnosis for use (indication)
#1 DEMENTIA
#2 UNKNOWN

5. Event abated after use stopped or dose reduced
#1 [x] yes [ ] no [ ] doesn't apply
#2 [x] yes [ ] no [ ] doesn't apply

6. Lot # (if known)
#1
#2

7. Exp. date (if known)
#1
#2

8. Event reappeared after reintroduction
#1 [ ] yes [ ] no [ ] doesn't apply
#2 [ ] yes [ ] no [x] doesn't apply

9. NDC # - for product problems only (if known)

10. Concomitant medical products and therapy dates (exclude treatment of event)
No concomitant drugs reported

D. All manufacturers

1. Contact office - name/address (& mfring site for devices)
EISAI, INC.
Drug Safety
500 Frank W. Burr Blvd.
Teaneck NJ 07666-6741
USA
(Printing Unit)

2. Phone number: 201-692-9160

3. Report source (check all that apply)
- [ ] foreign
- [ ] study
- [ ] literature
- [ ] consumer
- [x] health professional
- [ ] user facility
- [ ] company representative
- [ ] distributor
- [ ] ____

4. Date received by manufacturer (mm/dd/yyyy): 01/28/99

5. (A)NDA # 20,690
IND #
PLA #
pre-1938 [ ] yes
OTC product [ ] yes

6. If IND, protocol #

7. Type of report (check all that apply)
- [ ] 5-day [x] 15-day
- [ ] 10-day [ ] periodic
- [ ] initial [x] follow-up # 1

8. Adverse event term(s)
1) COMA
2) CONFUSION
3) LIVER FUNCTION TESTS ABNORMAL NOS
4) BRADYCARDIA

9. Mfr. report number: A001-002-002990

E. Initial reporter

1. Name, address & phone #
MS. [redacted]
UNIVERSITY [redacted] CENTER
[redacted] MEDICAL CENTER
USA
Phone # [redacted]

2. Health professional? [x] yes [ ] no

3. Occupation: Poison Control Center

4. Initial reporter also sent report to FDA [ ] yes [ ] no [x] unk

3500A Facsimile

Submission of a report does not constitute an admission that medical personnel, user facility, distributor, manufacturer or product caused or contributed to the event.

B. Adverse event or product problem

B.5 Describe event or problem (Cont...)

Jan/18/99: A health care professional from the Poison control center contacted the company. Cholinesterase level 8312 U/L. Pseudocholinesterase level was 1954 U/L (Ref Range 1900-3800 U/L).
Jan/19/99: Follow-up with the health care professional reveals the patient remains confused but responsive; it is not known if the patient took an intentional overdose . The patient is receiving Mucomyst (acetylcysteine) for the treatment of acetaminophen overdose. The patient's ALT and AST were both "under 100."

Jan/20/99: Resident Physician was contacted in follow-up, he indicated the patient remains responsive but demented. He indicated that the family feels the patient has not returned to baseline cognition. He indicated that he felt she was probably at baseline as the family was not in close contact with the patient at all times. The patient's bradycardia has resolved and heart rate is in the 80's. AST level was 33 UI/L and the ALT was 72 UI/L.

ADDITIONAL INFORMATION RECEIVED: JAN/28/99:
The resident physician at the Poison Control Center of The University of [redacted] was contacted in follow-up.
Jan/21 or 22/99: Another cholinesterase level was drawn , results pending.
Jan/22/99: The patient was discharged form the hospital. At the time of discharge the patient was more alert and brighter but remained demented with cognitive deficits, which the physician felt was probably her baseline.

B.6 Relevant tests/laboratory data, including dates (Cont...)

Jan/18/99:
Cholinesterase level 8312 U/L
Pseudocholinesterase level 1954 U/L

Jan/19/99:
AST and ALT = < "100"

Jan/20/99:
AST 33 IU/L
ALT 72 UI /L

Jan/21/or 22/99: Cholinesterase level drawn: results pending.

C. Suspect medication (Cont...)

Seq No.	: 1
C.1 Suspect medication	: ARICEPT (DONEPEZIL)
C.2 Dose, frequency & route used	: 2) NA, Per oral
C.3 Therapy Dates (or duration)	: 2) 01/17/99 - 01/17/99

Individual Safety Report
3192074-3-00-02

DSS

FEB 5 1999

ADVERSE EVENT REPORTING SYSTEM

RECEIVED
FEB 04 1999
BY: